Role of Eg5 in Prognosis Prediction and Treatment of Hepatocellular Carcinoma

Background: The kinesin Eg5, a mitosis-associated protein, is overexpressed in many cancers. Here we explored the clinical signicance of Eg5 in HCC. Methods: HCC tissues from surgical resection were collected. Total RNA was prepared from tumorous and nontumorous parts. Eg5 expression levels were correlated with overall survival (OS) and disease-free survival (DFS). In vitro ecacy of LGI-147, a specic Eg5 inhibitor, was tested in HCC cell lines. In vivo ecacy of Eg5 inhibition was investigated in a xenograft model. Results: A total of 108 HCC samples were included. The patients were divided into three tertile groups with high, medium, and low Eg5 expression levels. OS of patients with low Eg5 expression was better than that of patients with medium and high Eg5 expression (median, 155.6 vs. 75.3 vs. 57.7 months, p = 0.002). DFS of patients with low Eg5 expression was also better than that of patients with medium and high Eg5 expression (median, 126.3 vs. 46.2 vs. 39.4 months, p = 0.001). In multivariate analyses, the associations between Eg5 expression and OS (p < 0.001) or DFS remained (p < 0.001). LGI-147 reduced cell growth via cell cycle arrest and apoptosis and induced accumulation of abnormal mitotic cells. In the xenograft model, the tumor growth rate under LGI-147 treatment was signicantly slower than the control. Conclusion: High Eg5 expression was associated with poor HCC prognosis. In vitro and in vivo evidence suggests that Eg5 may be a reasonable therapeutic target for HCC.


Background
Treatment for unresectable hepatocellular carcinoma (HCC) remains challenging despite improvements in treatment modalities including antiangiogenic targeted therapy and immune checkpoint inhibitors [1].
For diseases refractory or unamenable to transarterial chemoembolization, combined targeted therapy and immunotherapy can produce an objective response rate of approximately 30% [2][3][4][5], which leaves much room for improvement. Moreover, patients who fail rst-line systemic therapy exhibit poor prognosis [6]. Therefore, novel modalities of systemic therapies for HCC are urgently required.
We and other investigators have discovered that mitosis regulators, such as Aurora kinases A and B, are frequently overexpressed in HCC cells and have been associated with poor HCC prognosis [7][8][9]. Kinesins are a superfamily of motor proteins that participate in the organelle transport and mitosis [10,11].
Overexpression of Eg5, a kinesin, may lead to genomic instability and tumor formation in mice [12]. High Eg5 expression in tumor tissues is also associated with poor prognosis in breast and laryngeal cancers [13,14].
In addition, mitosis regulators also can serve as the potential cancer treatment therapeutic targets.
Taxanes and vinka alkaloids, chemotherapeutic agents effective against multiple cancers, interfere with microtubules and hence mitotic function [15]. Numerous studies have indicated the potential of kinesin inhibitors as treatment for various cancers [10,16]. Among them, Eg5 inhibitors have been reported to be effective in preclinical models of melanoma as well as breast, ovarian and prostate cancers [17][18][19][20].
The role of Eg5 in prognosis prediction and as a therapeutic target related to HCC is unclear. We examined the association between Eg5 expression in surgically resected tumor tissues and HCC prognosis. We also tested the in vitro and in vivo e cacy of Eg5 inhibition against HCC.

Patient samples
We assessed unifocal primary HCC tissues from 108 patients who underwent surgical total tumor resection between January 1987 and January 2008. Comprehensive pathologic assessments and regular clinical follow-ups were performed at the National Taiwan University Hospital (NTUH), as described previously [7]. Patients with evidence of regional lymph node or distant metastasis were excluded. This study was approved by the Research Ethics Committee of NTUH.

Quantitative reverse transcription-polymerase chain reaction
The extraction of total RNA and complementary DNA (cDNA) of paired HCCs and nontumorous liver tissues was prepared as described previously [21]. Gene expression assays for Eg5 were performed using quantitative reverse transcription polymerase chain reaction (RT-PCR) with the TaqMan® Gene Expression Master Mix and a Eg5 probe (Hs00189698_m1), with GAPDH as a control (Hs99999905_m1; Applied Biosystems, Foster City, CA, USA). The expression levels of Eg5 and GAPDH were determined through 45 thermal cycles of 30 s at 95 °C and 60 s at 60 °C. All experiments were performed in duplicate.
Quantitative data were expressed as the numbers of cycles required to reach a speci c threshold of detection (C T value) during the exponential ampli cation phase. The relative quanti cation of Eg5 expression was calculated using the comparative threshold cycle (2 −∆∆CT ) method [∆C T = C T (Eg5) − C T (GAPDH) , ∆∆C T = ∆C T (tumor tissue) − ∆C T (normal liver tissue)] [21].

Cell culture and reagents
The liver cancer cell lines HepG2, Hep3B, and PLC5 were maintained in Dulbecco's modi ed Eagle's medium plus 10% fetal bovine serum, supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin. Cells were cultured in a humidi ed incubator with 5% CO 2 at an air temperature of 37 °C.
LGI-147 was provided by Novartis Pharma AG (Basel, Switzerland). The biochemical half maximal inhibitory concentration (IC 50 ) of LGI147 for Eg5 is 0.6 nM (unpublished data provided by Novartis Pharma AG).

Cell viability
A total of 5 × 10 4 liver cancer cells were seeded in 6-well plates. After overnight culture, cells were treated with dimethyl sulfoxide or LGI-147 for 72 h. Cell viability was quanti ed using the trypan blue exclusion assay as described previously [7].

Cell cycle and apoptosis analyses
Cells in logarithmic growth were incubated with either LGI-147 or dimethyl sulfoxide for 24 to 72 h. Cells were trypsinized and xed in 70% methanol overnight and labeled with 0.5 to 1 mL propidium iodide at 50 µg/mL. Cell cycle pro les were determined using a FACSCaliber (Becton Dickinson, San Jose, CA, USA).
The sub-G1 assay by ow cytometry was used to determine apoptotic cell numbers. Western blotting was performed according to standard protocols using anti-cleaved poly(ADP-ribose) polymerase (PARP) antibody (Cell Signaling Technology, Beverly, MA, USA) and an anti-β-actin antibody (Sigma-Aldrich) to detect apoptotic signals.

Xenograft animal studies
Animal studies were conducted according to the guidelines of the Institutional Animal Care and Use Committee of NTUH.
(Taipei, Taiwan). PLC5 cells were injected subcutaneously into the right anks (2 × 10 6 / ank in 200µL) of the mice. When tumor volume reached approximately 200 mm 3 , the mice were treated with intravenous injection of LGI-147 or a vehicle twice a week. Tumor size was estimated twice a week, and the body weight was monitored daily.

Statistical analysis
All statistical analyses were performed using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).
A two-sided p value of ≤ 0.05 was considered to be statistically signi cant. For continuous variables such as tumor size and Eg5 expression, either the independent t test or one-way analysis of variance was used for between-group comparisons. The Pearson correlation coe cient was calculated to examine the correlation between age and Eg5 expression. The Kaplan-Meier method was used to estimate survival outcomes. To compare survival between groups, the log-rank test and a Cox proportional hazards model were used in univariate and multivariate analysis, respectively. Overall survival (OS) was de ned as the period from the surgery date until the date of death. Disease-free survival (DFS) denoted the period from the surgery date until tumor recurrence or the date of death, whichever occurred rst. Minimal follow-up duration was 5 years. At the end of the follow-up session in August 2019, only 17 patients were still alive.

Eg5 expression and HCC prognosis
A total of 108 unifocal primary HCC samples were included. The mean patient age was 54.7 years, and 19% were female (Table 1). Hepatitis B virus and hepatitis C virus infection was detected in 69% and 29% of patients, respectively. The mean RNA expression of Eg5 in tumor tissues compared with that in nontumor tissues was 8.3 (standard deviation 16.0). Eg5 expression was not signi cantly associated with patient demographic characteristics, tumor extent, or tumor grade (Table 1).  1B). Thus, the patients with low Eg5 expression exhibited the best survival outcomes, as compared with two groups of patients with high and median Eg5 expression, in OS (p = 0.002) and DFS (p = 0.001).
In other words, high EG5 expression seems to enhance tumor progression and hence poor patient survival.
After adjustment for other clinicopathological variables, including gender, age, tumor stage, hepatitis etiology, and α-fetoprotein level, low Eg5 expression remained an independent predictor of better OS (hazard ratio [HR] 0.377, p < 0.001) and DFS (HR 0.334, p < 0.001; Table 2). LGI-147 reduced cell viability in all cell lines in a dose-dependent manner ( Fig. 2A). The IC 50 at 72 h for the HepG2, Hep3B, and PLC5 cells were 53.59, 59.6, and 43.47 pM, respectively. We examined the speci c kinase inhibitory activity of LGI-147 using the cell-free kinesin ATPase assay.

Cellular effects of Eg5 inhibition in HCC cells
To analyze the mitotic interference of Eg5 inhibition, we examined the morphological changes in mitotic spindles and chromosomes in HCC cells treated with LGI-147. The accumulation of abnormal mitotic cells induced by LGI-147 was dose dependent. After treatment with 40 pM of LGI-147, more than 75% of HCC cells showed abnormal mitotic features (Figs. 2C and 2D).
Because mitotic interference may induce cell cycle disturbance and cell death, we investigated the effects of LGI-147 on HCC cell cycle progression and apoptosis. As shown in Fig. 3A, Eg5 inhibition by LGI-147 treatment resulted in time-dependent cell cycle arrest and accumulation of tetraploid cells.
LGI-147 treatment also led to the appearance of octoploid cells, which preceded cell death, particularly in the PLC5 cell line.

Eg5 inhibition reduced in vivo HCC tumor growth
To determine the in vivo antitumor e cacy of LGI-147, a PLC5 xenograft model was established. PLC5 tumor growth was signi cantly suppressed by LGI-147 treatment (Fig. 4B). At day 14 of LGI-147 treatment, the mean tumor volumes of mice treated at 2 mg/Kg (851.97 mm 3 ) and 4 mg/kg (666.94 mm 3 ) were signi cantly lower than that of the control group (1382.21 mm 3 ; p < 0.05 for both). Mice weight did not differ signi cantly between groups (Fig. 4C).

Discussion
In this study, we observed an association between high tumor expression of Eg5 and poor HCC prognosis. Inhibition of cell proliferation through mitosis is a clinically effective anticancer intervention [23]. As our previous studies have demonstrated, the overexpression of Aurora kinases A and B, essential mitotic kinases, in HCC cells is associated with poor HCC prognosis [7,9]. Furthermore, Aurora kinase inhibitors have potent anticancer effects in human HCC [7,9]. Elucidation of the prognostic signi cance of Eg5 expression and the antitumor e cacy of speci c Eg5 inhibitors is essential to establish Eg5 as a therapeutic target for HCC. Therefore, the ndings of the present study provide a rationale for the clinical development of speci c Eg5 inhibitors for HCC treatment. Our ndings regarding the prognostic value of Eg5 expression are generally consistent with those of a previous study [24], although that study did not analyze DFS and used immunohistochemical staining, rather than quanti ed RNA expression, to evaluate tumor Eg5 expression levels.
The past decade has seen the identi cation of multiple anticancer small-molecule inhibitors targeting mitotic machinery, including Aurora kinases, Polo-like kinase 1, Eg5, and CENP-E. Their cellular consequences are typically disturbance of the cell cycle, suppression of cell proliferation, and induction of apoptosis at mitotic phase or following mitotic slippage [25]. Eg5 is a promising anticancer therapeutic target because, as with other kinesins such as CENP-E, it is critically involved in centrosome maturation, spindle assembly, chromosome segregation, and cytokinesis [16]. In the current study, we used LGI-147, a speci c Eg5 inhibitor that did not inhibit the activity of other kinesins such as CENP-E, MKLP-1, and BimC. The IC 50 of LGI-147 on cell viability at the pM level was extremely low. The therapeutic potential of other Eg5 inhibitors such as AZD4877 [26,27] and lanesib [28][29][30] has been demonstrated in several phase I or II clinical trials for cancers other than HCC. Our ndings may provide a basis for the development of LGI-147 or other Eg5 inhibitors as HCC therapeutics.
Our study had some limitations. First, we only used one method of Eg5 inhibition because we did not have access to Eg5 inhibitors other than LGI-147. However, as mentioned, LGI-147 had high speci city; therefore, the possibility of an off-target effect of LGI-147 as the primary mechanism is low. Second, we did not examine the peripheral blood cell counts of mice under LGI-147 treatment. Because mitosis inhibitors may affect all dividing cells, bone marrow suppression can be primary toxicity. However, such problems can be addressed in phase 1 clinical trials or resolved through scheduling.

Conclusions
High Eg5 expression was associated with poor HCC prognosis. Eg5 inhibition with LGI-147 demonstrated promising in vitro and in vivo e cacy against HCC cells, suggesting that Eg5 is a potential clinical prognostic factor and therapeutic target for HCC. Availability of data and materials: